Repothesis.com

The same molecule can be a billion-dollar asset in one indication and worthless in another…Most repositioning analysis can’t tell the difference fast enough.

Repositioning is the source of roughly 30% of FDA approvals — a $35B+ opportunity. Yet a single BD&L evaluation still burns 200+ analyst hours and $25K–$75K in consultant fees, and often leaves the fundamental questions unanswered.

Repothesis scores every compound–indication pair on two independent axes — scientific evidence and commercial viability — and classifies it into a clear, defensible recommendation. Independently graded, with no affiliate relationships and no paid placement. The result is a board-ready repositioning call at a fraction of the time and cost of a manual evaluation.

Built from published evidence, for pharma BD&L teams, biotech strategy groups, VCs, and rare-disease foundations — with orphan economics weighted properly, so a 5,000-patient indication can correctly outrank a crowded blockbuster market.

To discuss a compound or indication, or to schedule a 1:1 at BIO or anytime, email Chris Hoover at chris@scientari.com. Explore the full methodology, verticals, and product formats at repothesis.com.